Synthesis and biological evaluation of new 4-thiazolidinone derivatives

References

• Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. (1999). Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. J Am Med Assoc, 282, 677–686.
   PubMed Web of Science ®Google Scholar
• Bass JB, Farer LS, Hopewell PC, O’Brein R, Jacob RF, Ruben F, Snider DE Jr, Thornton G. (1994). Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med, 149, 1359–1374.
   PubMed Web of Science ®Google Scholar
• Farmer P, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. (1998). The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis, 2, 869–876.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2000). Anti-Tuberculosis Drug Resistance in the World-Report No. 2. Prevalence and Trends. Geneva, Switzerland: WHO.
   Google Scholar
• Ginsburg AS, Grosset JH, Bishai WR. (2003). Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis, 3, 432–442.
   PubMed Web of Science ®Google Scholar
• Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR. (1994). Transmission of tuberculosis in New York city—an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med, 330, 1710–1716.
   PubMed Web of Science ®Google Scholar
• Ulusoy N. (2002). Synthesis and antituberculosis activity of cycloalkylidene-hydrazide and 4-aza-1-thiaspiro[4.5]decan-3-one derivatives of imidazo[2,1-b]thiazole. Arzneim-Forsch/Drug Res, 52, 565–571.
   PubMed Web of Science ®Google Scholar
• Srivastava T, Gaikwad AK, Haq W, Sinha S, Kati SB. (2005). Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents. Arkivoc, ii, 120–130.
   Web of Science ®Google Scholar
• Bukowski L, Janowiec M, Zwolska-Kwiek Z, Andrezejczyk Z. (1998). Some reactions of 2-cyanomethylimidazo[4,5-b]pyridine with isothiocyanates. Antituberculotic activity of the obtained compounds. Pharmazie, 53, 373–376.
   PubMed Web of Science ®Google Scholar
• Babaoglu K, Page MA, Jones VC, McNeil MR, Dong C, Naismith JH, Lee RE. (2003). Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett, 13, 3227–3230.
   PubMed Web of Science ®Google Scholar
• Çapan G, Ulusoy N, Ergenç N, Kiraz M. (1999). New 6-phenylimidazo[2,1-b]thiazole derivatives: synthesis and antifungal activity. Monatsh Chem, 130, 1399–1407.
   Web of Science ®Google Scholar
• Karali N, İlhan E, Gürsoy A, Kiraz M. (1998). New cyclohexlidenehydrazide and 4-aza-1-thiaspiro[4,5]decan-3-one derivatives of 3-phenyl-4(3H)-quinazolinones. Farmaco, 53, 346–349.
   Google Scholar
• Fahmy HTY. (2001). Synthesis of some new triazoles as potential antifungal agents. Boll Chim Farmaco, 140, 422–427.
   PubMedGoogle Scholar
• Barreca ML, Chimirri A, Luca LD, Monforte AM, Monforte P, Rao M, Zappalá M, Balzarini J, De Clercq E, Pannecouque C, Witvrouw P. (2001). Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. Bioorg Med Chem Lett, 11, 1793–1796.
   PubMed Web of Science ®Google Scholar
• Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalá M. (2002). Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Farmaco, 57, 747–751.
   PubMedGoogle Scholar
• Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalá M. (2003). Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Farmaco, 58, 115–120.
   PubMedGoogle Scholar
• Barreca ML, Chimirri A, De Clercq E, Luca LD, Monforte AM, Monforte P, Rao A, Zappalá M. (2003). Design and discovery of new potent RT inhibitors. Farmaco, 58, 259–263.
   PubMedGoogle Scholar
• Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Luca LD, Monforte AM, Monforte P, Pannecouque C, Zappalá M. (2004). Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Farmaco, 59, 33–39.
   PubMedGoogle Scholar
• Ragab FA, Eid NM, El-Tawab HA. (1997). Synthesis and anticonvulsant activity of new thiazolidinone and thioxoimidazolidinone derivatives derived from furochromones. Pharmazie, 52, 926–929.
   PubMed Web of Science ®Google Scholar
• Kaynak FB, Öztürk D, Özbey S, Çapan G. (2005). New N’-alkylidene/cycloalkylidene derivatives of 5-methyl-3-phenyl-1H-indole-2-carbohydrazide: synthesis, crystal structure, and quantum mechanical calculations. J Mol Struct, 740, 213–221.
   Web of Science ®Google Scholar
• Bicking JB, Bock MG, Cragoe EJ, Dipardo RM, Gould NP, Holltz WJ, Lee TJ, Robb CM, Smith RL, Springer JP, Blaine EH. (1983). Prostaglandin isosteres. 2. Chain-modified thiazolidinone prostaglandin analogs as renal vasodilators. J Med Chem, 26, 342–348.
   PubMed Web of Science ®Google Scholar
• Güzel Ö, İlhan E, Salman A. (2006). Synthesis and antimycobacterial activity of new 2-hydroxy-N-(3-oxo-1-thia-4-azaspiro[4.4]non-4-yl)/(3-oxo-1-thia-4-azaspiro-[4.5]dec-4-yl)-2,2-diphenylacetamide derivatives. Monatsh Chem, 137, 795–801.
   Web of Science ®Google Scholar
• Karalı N, İlhan E, Gürsoy A, Kiraz M. (1998). New cyclohexylidenhydrazide and 4-aza-1-thiaspiro[4,5]decan-3-one derivatives of 3-phenyl-4-(3H)-quinazolinones. Farmaco, 52, 1–5.
   Google Scholar
• Peter R, Hellenbrand J, Mengerink Y, Van der Wal Sj J. (2004). On-line determination of carboxylic acids, aldehydes and ketones by high-performance liquid chromatography-diode array detection-atmospheric pressure chemical ionisation mass spectrometry after derivatization with 2-nitrophenylhydrazine. Chromatogr A, 1031, 35–50.
   PubMed Web of Science ®Google Scholar
• Çapan G, Ulusoy N, Ergenç N, Ekinci AC, Vidin A. (1996). Synthesis and anticonvulsant activity of new 3-[(2-furyl)carbonyl]amino-4-thiazolidinone and 2-[(furyl)carbonyl]hydrazono-4-thiazoline derivatives. Farmaco, 51, 729–732.
   PubMedGoogle Scholar
• Collins LA, Franzblau SG. (1997). Microplate Alamar Blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother, 41, 1004–1009.
   PubMed Web of Science ®Google Scholar
• Alley MC, Scudiero DA, Monks PA, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. (1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res, 48, 589–601.
   PubMed Web of Science ®Google Scholar
• Grever MR, Schepartz SA, Chabner BA. (1992). The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin Oncol, 19(6), 622.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. (1995). Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel Res, 34, 91–109.
   Web of Science ®Google Scholar